EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Allergy Therapeutics EBITDA Margin % Related Terms
Allergy Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HHU vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics (FRA:HHU) has a EBITDA Margin % of -36.46% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Allergy Therapeutics and its competitors. According to the industry distribution chart, Allergy Therapeutics ranks #860 out of 955 companies in the Drug Manufacturers industry, placing it in the top 90.1%.
Is Allergy Therapeutics' EBITDA Margin % too high?
Allergy Therapeutics' current EBITDA Margin % is -36.46%. Based on the distribution chart, Allergy Therapeutics ranks #860 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Allergy Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Allergy Therapeutics' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #860 out of 955 companies for EBITDA Margin %. This places Allergy Therapeutics in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current EBITDA Margin % is -36.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (FRA:HHU) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.07 — trading 141.7% above its estimated fair value. The current EBITDA Margin % is -36.46%. Allergy Therapeutics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Allergy Therapeutics (FRA:HHU), the current EBITDA Margin % is -36.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allergy Therapeutics (FRA:HHU) Overvalued in 2026?
Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued.
The current stock price of €0.07 is trading 141.7% above its estimated GF Value™ of €0.03.
GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:HHU:
EBITDA Margin %: -36.46%
GF Value™: €0.03 vs. price of €0.07 (141.7% above fair value)
No single metric tells the full story. See the FRA:HHU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
39GF Score
Get the complete analysis for FRA:HHU
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HHU has been successfully added to your 
